
    
      This is a Phase I placebo-controlled study to assess the pharmacokinetics, safety and
      tolerability of 2 doses of anifrolumab via the subcutaneous (SC) route of administration and
      1 dose of anifrolumab via intravenous (IV) route in healthy subjects
    
  